Fundraising Fox
/Companies
Sign in

AvenCell

65 employees on LinkedIn · 7 known investors

Find your way into AvenCell

Sign up to see every warm intro you have to AvenCell

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AvenCell team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.

BiotechLongevityMedical Devices

Founders & leadership

ASAndrew Schiermeier
Andrew SchiermeierChief Executive Officer

Investors · 7

Blackstone Life Sciences✓ confirmed by AvenCellNew York · $20M – $60M

How we know: the company's own site · prnewswire.com · Not right? Tell us

Eight Roads Ventureslisted by Eight Roads VenturesMumbai · $5M – $30M

How we know: Eight Roads Ventures's portfolio page · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · prnewswire.com · Not right? Tell us

NYBC Ventureslisted by NYBC VenturesNew York

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 2

Eight Roads Ventures JapanPiper Heartland Healthcare Capital

Funding

SEC filings, press & company announcements

$112M disclosed across 1 round · 2024

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

AgenusAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.
Applied StemCellApplied StemCell is a genome engineering platform company that develops proprietary technologies and iPSC expertise to enable safe, scalable integration of large DNA payloads into the mammalian genome for gene and cell-based medicine. The company provides end-to-end solutions for academia and biopharma partners to accelerate therapeutic development.
Anavex Life SciencesAnavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its lead compound is ANAVEX 2-73 (blarcamesine), targeting early Alzheimer's and neurodevelopmental rare diseases.

Companies working in the same space as AvenCell.

In the news

AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignanciesprnewswire.com · Apr 2026AvenCell Raises $112M in Series B Fundingfinsmes.com · Oct 2024AvenCell Raises $112 Million in Series B; Funding Led by Novo Holdingsprnewswire.com · Oct 2024

Frequently asked questions

What does AvenCell do?
AvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.
Who are AvenCell's investors?
AvenCell's investors include Novo Holdings, Blackstone Life Sciences, Eight Roads Ventures, F-Prime Capital, NYBC Ventures.
How much funding has AvenCell raised?
AvenCell has disclosed $112M raised across 1 round.